CN101142233A - 抑制cathelin样蛋白hCAP18/LL-17的试剂 - Google Patents

抑制cathelin样蛋白hCAP18/LL-17的试剂 Download PDF

Info

Publication number
CN101142233A
CN101142233A CNA2005800482770A CN200580048277A CN101142233A CN 101142233 A CN101142233 A CN 101142233A CN A2005800482770 A CNA2005800482770 A CN A2005800482770A CN 200580048277 A CN200580048277 A CN 200580048277A CN 101142233 A CN101142233 A CN 101142233A
Authority
CN
China
Prior art keywords
reagent
hcap18
cells
cell
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800482770A
Other languages
English (en)
Chinese (zh)
Inventor
莫娜·斯塔勒
约翰·海尔博恩
玛加丽塔·弗罗姆·尼尔松
冈特·韦博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipopeptide AB
Original Assignee
Lipopeptide AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopeptide AB filed Critical Lipopeptide AB
Publication of CN101142233A publication Critical patent/CN101142233A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005800482770A 2004-12-22 2005-12-16 抑制cathelin样蛋白hCAP18/LL-17的试剂 Pending CN101142233A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63775904P 2004-12-22 2004-12-22
US60/637,759 2004-12-22

Publications (1)

Publication Number Publication Date
CN101142233A true CN101142233A (zh) 2008-03-12

Family

ID=36283015

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800482770A Pending CN101142233A (zh) 2004-12-22 2005-12-16 抑制cathelin样蛋白hCAP18/LL-17的试剂

Country Status (6)

Country Link
US (1) US7741275B2 (enExample)
EP (1) EP1846444A2 (enExample)
JP (1) JP2008525005A (enExample)
CN (1) CN101142233A (enExample)
CA (1) CA2593956A1 (enExample)
WO (1) WO2006067402A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101571549B (zh) * 2008-04-30 2013-08-14 上海泽润生物科技有限公司 Vero细胞HCP检测试剂盒及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608797D0 (en) * 2006-05-04 2006-06-14 Lipopeptide Ab Novel agents and the use thereof
WO2007148078A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent
US20120315290A1 (en) * 2006-12-15 2012-12-13 Board Of Regents, The University Of Texas System Inhibitors of ll-37 mediated immune reactivity to self nucleic acids
DK3252068T3 (da) 2009-10-12 2025-08-25 Larry J Smith Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro
CN111973805B (zh) * 2019-08-16 2022-03-01 苏州吉美瑞生医学科技有限公司 抗菌肽hCAP18/LL-37在抗感染生物工程肺中的应用
JP2023539590A (ja) * 2020-08-26 2023-09-15 シラ セラピューティック インコーポレイティッド 吸入用治療剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
PL178438B1 (pl) 1994-02-04 2000-04-28 Scotia Lipidteknik Ab Preparat dwuwarstwy lipidowej, środek farmaceutyczny zawierający preparat dwuwarstwy lipidowej i sposób wytwarzania środka farmaceutycznego
CN1091591C (zh) 1994-02-04 2002-10-02 利珀克尔集团公司 亲脂载体制剂
JP3117145B2 (ja) 1994-02-04 2000-12-11 スコーツイア・リピツドテクニク・アクチエボラーグ 水中油エマルジョン
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
JPWO2004009640A1 (ja) 2002-07-22 2005-11-17 生化学工業株式会社 抗菌性ペプチドに対する抗体及びその利用
AU2003288507A1 (en) * 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
WO2004098536A2 (en) * 2003-03-06 2004-11-18 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101571549B (zh) * 2008-04-30 2013-08-14 上海泽润生物科技有限公司 Vero细胞HCP检测试剂盒及其应用

Also Published As

Publication number Publication date
WO2006067402A2 (en) 2006-06-29
JP2008525005A (ja) 2008-07-17
WO2006067402A3 (en) 2006-09-08
EP1846444A2 (en) 2007-10-24
US7741275B2 (en) 2010-06-22
CA2593956A1 (en) 2006-06-29
US20080187530A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
JP2018516545A (ja) Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法
CN112512577A (zh) 结直肠癌的治疗、预防和预后检测的方法
CN111526894A (zh) 将chi3l1抑制剂作为有效成分的用于预防或治疗癌症的肺转移的药物组合物
US7741275B2 (en) Agents and use thereof
JP2008525479A (ja) トレフォイル因子およびそれを用いた増殖性疾患の処置方法
WO2007103876A2 (en) Cancer therapeutic
CN103068403A (zh) 用于含有癌干细胞的或由其起源的癌的治疗、预防和诊断的方法和组合物
US8404655B2 (en) Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity
WO2005092393A1 (ja) Wt1遺伝子の発現を抑制するマイクロrnaおよびその利用
US20160200804A1 (en) Compositions and methods for treating anaplastic thyroid cancer
JP2019525903A (ja) 転移性癌の診断及び治療の方法
CN101479385A (zh) 用于乳腺癌治疗的hcap18/ll-37抑制剂
EP2561885A2 (en) Use of hades as tumor suppressor target
CN101478988A (zh) 联合治疗产品及其应用
US20220162616A1 (en) Dual inhibition of plexin-b1 and plexin-b2
WO2006016574A1 (ja) ＲＮＡｉを利用した抗腫瘍剤
EP4434544A9 (en) Cd300ld inhibitor and use thereof in preparation of tumor immunotherapy product
US20260117226A1 (en) Long non-coding rnas as target for treating fibrosis and cancer
US11136368B2 (en) Cancer treatment using CX26 blocking peptides
Balestra Dissecting the role of zyxin as a mediator of aggressiveness in Ewing sarcoma
TW202502371A (zh) 用於治療癌症的與ｂｒａｆ抑制劑的組合療法
HK40119842A (zh) 用於预防t细胞耗竭的组合物和方法
KR20200122183A (ko) 암의 예방 또는 치료용 약학 조성물
KR20140086578A (ko) ＨＩＦ­１α ｓｉＲＮＡ 및 항산화제를 함유하는 재발암 또는 내성암의 치료 또는 예방용 약제학적 조성물
WO2010015032A1 (en) Methods of treating and preventing glucose toxicity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080312